A detailed history of Ingalls & Snyder LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Ingalls & Snyder LLC holds 63,049 shares of AZN stock, worth $4.74 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
63,049
Previous 63,990 1.47%
Holding current value
$4.74 Million
Previous $4.34 Million 13.43%
% of portfolio
0.21%
Previous 0.19%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$66.81 - $80.83 $62,868 - $76,061
-941 Reduced 1.47%
63,049 $4.92 Million
Q1 2024

May 13, 2024

SELL
$61.03 - $69.57 $8,788 - $10,018
-144 Reduced 0.22%
63,990 $4.34 Million
Q4 2023

Jan 29, 2024

SELL
$61.89 - $69.28 $96,424 - $107,938
-1,558 Reduced 2.37%
64,134 $4.32 Million
Q3 2023

Nov 02, 2023

BUY
$64.85 - $71.7 $188,583 - $208,503
2,908 Added 4.63%
65,692 $4.45 Million
Q2 2023

Jul 27, 2023

SELL
$69.91 - $75.81 $29,781 - $32,295
-426 Reduced 0.67%
62,784 $4.49 Million
Q1 2023

May 09, 2023

SELL
$63.15 - $71.6 $31,196 - $35,370
-494 Reduced 0.78%
63,210 $4.39 Million
Q4 2022

Jan 31, 2023

SELL
$54.21 - $70.44 $273,543 - $355,440
-5,046 Reduced 7.34%
63,704 $4.32 Million
Q3 2022

Oct 21, 2022

SELL
$53.02 - $135.75 $8,960 - $22,941
-169 Reduced 0.25%
68,750 $3.77 Million
Q2 2022

Aug 11, 2022

SELL
$59.26 - $71.14 $83,734 - $100,520
-1,413 Reduced 2.01%
68,919 $4.55 Million
Q1 2022

May 09, 2022

SELL
$55.72 - $67.12 $219,536 - $264,452
-3,940 Reduced 5.3%
70,332 $4.67 Million
Q4 2021

Feb 11, 2022

SELL
$54.02 - $63.83 $21,824 - $25,787
-404 Reduced 0.54%
74,272 $4.33 Million
Q3 2021

Oct 27, 2021

BUY
$55.56 - $60.79 $2.35 Million - $2.57 Million
42,302 Added 130.67%
74,676 $4.49 Million
Q2 2021

Aug 03, 2021

SELL
$48.42 - $60.18 $192,227 - $238,914
-3,970 Reduced 10.92%
32,374 $1.94 Million
Q1 2021

Apr 21, 2021

SELL
$47.16 - $54.44 $13,440 - $15,515
-285 Reduced 0.78%
36,344 $1.81 Million
Q4 2020

Jan 27, 2021

BUY
$48.52 - $58.02 $1.78 Million - $2.13 Million
36,629 New
36,629 $1.83 Million
Q3 2020

Oct 21, 2020

SELL
$53.07 - $61.1 $1.3 Million - $1.5 Million
-24,579 Closed
0 $0
Q2 2020

Jul 31, 2020

SELL
$43.1 - $55.31 $92,234 - $118,363
-2,140 Reduced 8.01%
24,579 $1.3 Million
Q1 2020

Apr 22, 2020

BUY
$37.79 - $51.33 $1.01 Million - $1.37 Million
26,719 New
26,719 $1.19 Million
Q4 2019

Jan 15, 2020

SELL
$42.46 - $50.46 $1.05 Million - $1.24 Million
-24,616 Closed
0 $0
Q3 2019

Oct 16, 2019

SELL
$40.12 - $45.47 $2,005 - $2,273
-50 Reduced 0.2%
24,616 $1.1 Million
Q2 2019

Jul 11, 2019

SELL
$37.28 - $41.68 $44,139 - $49,349
-1,184 Reduced 4.58%
24,666 $1.02 Million
Q4 2018

Jan 24, 2019

SELL
$36.86 - $41.49 $30,630 - $34,478
-831 Reduced 3.11%
25,850 $982,000
Q3 2018

Oct 24, 2018

BUY
$34.76 - $39.72 $69,520 - $79,440
2,000 Added 8.1%
26,681 $1.06 Million
Q2 2018

Aug 10, 2018

SELL
$34.55 - $37.05 $8,292 - $8,892
-240 Reduced 0.96%
24,681 $867,000
Q4 2017

Jan 19, 2018

BUY
$32.09 - $34.78 $799,714 - $866,752
24,921
24,921 $865,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $233B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Ingalls & Snyder LLC Portfolio

Follow Ingalls & Snyder LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.